Novartis AG is restructuring the management of three of four business units, with plans to cut 550 marketing jobs in an effort to save $80 million annually starting in 2010, according to Joerg Reinhardt, head of the vaccines unit and chief operating officer. The restructuring is part of chief executive officer Daniel Vasella‘s plan to thwart losses of its best-selling drug Diovan due to generic competition.   Thomas Ebeling, head of the consumer health unit, is leaving the company and w...